Innovent and Anheart Report Novel TKI Effective in Phase II NSCLC Trial

Suzhou Innovent and Hangzhou AnHeart announced the Phase II trial of their partnered tyrosine kinase inhibitor was effective in TKI-naïve or Crizotinib-pretreated ROS1-positive NSCLC patients. The next-gen TKI targets ROS1 and NTRK. In 67 ROS1 TKI-naïve patients, the confirmed objective response rate was 92.5% and disease control rate 95.5%. In 38 crizotinib-pretreated patients, the cORR was 50% and DCR 78.9%. One year ago, Innovent acquired Greater China co-commercialization rights to the candidate from AnHeart in a deal that included an upfront payment, up to $189 million in milestones and royalties on sales. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues: